Coming full circle
In recent times, there have been a number of instances in the developed world, especially in the US, where pharmaceutical companies have been accused of being more concerned about profits rather than the health of people.

Rofecoxib and cardiovascular risk
Risk of adverse drug reactions to coxibs, as evaluated by clinical trials, differs from that observed in real medical practice, says Dr Krishan Maggon